Literature DB >> 31750901

Predicting success of desensitization after pegaspargase allergy.

Hope D Swanson1, John C Panetta1, Patricia J Barker1, Yiwei Liu1, Hiroto Inaba1, Mary V Relling1, Ching-Hon Pui1, Seth E Karol1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31750901      PMCID： PMC6940200          DOI： 10.1182/blood.2019003407

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  The impact of drug shortages on children with cancer--the example of mechlorethamine.

Authors:  Monika L Metzger; Amy Billett; Michael P Link
Journal:  N Engl J Med       Date:  2012-12-27       Impact factor: 91.245

2.  PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability.

Authors:  Anupam Verma; Karin Chen; Cynthia Bender; Nathan Gorney; Whitney Leonard; Phillip Barnette
Journal:  Pediatr Hematol Oncol       Date:  2019-07-12       Impact factor: 1.969

3.  Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].

Authors:  Emily K Browne; Christina Moore; April Sykes; Zhaohua Lu; Sima Jeha; Belinda N Mandrell
Journal:  J Pediatr Oncol Nurs       Date:  2017-11-21       Impact factor: 1.636

4.  Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.

Authors:  Wendy Stock; Dan Douer; Daniel J DeAngelo; Martha Arellano; Anjali Advani; Lloyd Damon; Tibor Kovacsovics; Mark Litzow; Michael Rytting; Gautam Borthakur; Archie Bleyer
Journal:  Leuk Lymphoma       Date:  2011-08-10

5.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Authors:  L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

6.  A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage.

Authors:  Bernard L Marini; Julia Brown; Lydia Benitez; Emily Walling; Raymond J Hutchinson; Rajen Mody; Rama Jasty Rao; Lynn Slagle; Lauren Bishop; Kristen Pettit; Dale L Bixby; Patrick W Burke; Anthony J Perissinotti
Journal:  Leuk Lymphoma       Date:  2019-05-17

7.  Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.

Authors:  Stacy L Cooper; David J Young; Caitlin J Bowen; Nicole M Arwood; Sarah G Poggi; Patrick A Brown
Journal:  Pediatr Blood Cancer       Date:  2019-05-16       Impact factor: 3.167

8.  PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.

Authors:  Louise Tram Henriksen; Arja Harila-Saari; Ellen Ruud; Jonas Abrahamsson; Kaie Pruunsild; Goda Vaitkeviciene; Ólafur Gísli Jónsson; Kjeld Schmiegelow; Mats Heyman; Henrik Schrøder; Birgitte Klug Albertsen
Journal:  Pediatr Blood Cancer       Date:  2014-11-21       Impact factor: 3.167

9.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Authors:  Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Jane O'Brien; Suzanne E Dahlberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Marshall Schorin; Mary V Relling; Harvey J Cohen; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

10.  Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.

Authors:  Umit M Sahiner; S Tolga Yavuz; Muge Gökce; Betul Buyuktiryaki; Ilhan Altan; Selin Aytac; Murat Tuncer; Ayfer Tuncer; Cansin Sackesen
Journal:  Pediatr Int       Date:  2013-08       Impact factor: 1.524
View more
  6 in total

1.  Comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.

Authors:  Wing H Tong
Journal:  J Oncol Pharm Pract       Date:  2021-04-13       Impact factor: 1.809

2.  An injectable excipient prevents anti-polyethylene glycol antibody-mediated hypersensitivity.

Authors:  Yiwei Liu; Colton A Smith; Monique Payton; David Jenkins; Laura J Janke; Mary V Relling
Journal:  Allergy       Date:  2021-05-29       Impact factor: 14.710

Review 3.  Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions.

Authors:  Maria Luisa Caballero; Matthew S Krantz; Santiago Quirce; Elizabeth J Phillips; Cosby A Stone
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-15

4.  The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience.

Authors:  Cassandra Rush; Kelly E Faulk; Zanette Kanani Bradley; Aubree Turner; Maija Krumins; Matthew Greenhawt
Journal:  J Allergy Clin Immunol Pract       Date:  2021-12-06

Review 5.  Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.

Authors:  Luke Maese; Rachel E Rau
Journal:  Front Pediatr       Date:  2022-06-30       Impact factor: 3.569

Review 6.  Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.

Authors:  André Baruchel; Patrick Brown; Carmelo Rizzari; Lewis Silverman; Inge van der Sluis; Benjamin Ole Wolthers; Kjeld Schmiegelow
Journal:  ESMO Open       Date:  2020-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.